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Abstract
The vasculature of the kidney is a heterogeneous structure, whose functional integrity is essential for the regulation
of renal function. Owing to the importance of the endothelium in vascular biology, chronic endothelial alterations
are therefore susceptible to impair multiple aspects of renal physiology and, in turn, to contribute to renal fibrosis.
Although systemic endothelial dysfunction is undoubtedly associated with chronic kidney disease, the role of the
renal endothelium in the initiation and the progression of renal fibrosis remains largely elusive. In this article, we
critically review recent evidence supporting direct and indirect contributions of renal endothelial alterations to
fibrosis in the kidney. Specifically, the potential implications of renal endothelial dysfunction and endothelial
paucity in parenchymal hypoxia, in the regulation of local inflammation, and in the generation of renal
mesenchymal cells are reviewed. We thereafter discuss therapeutic perspectives targeting renal endothelial
alterations during the initiation and the progression of renal fibrogenesis.
Introduction
The kidney receives approximately 20% of the cardiac
output, and many essential functions of the organ are
supported by the complex organization of renal micro-
vasculature. Therefore primitive or secondary pathologi-
cal changes in arterioles, glomerular capillaries, vasa
rectae and/or peritubular capillaries are susceptible to
impair different aspects of renal physiology and, in turn,
to contribute to the progression of chronic kidney dis-
ease (CKD). Endothelial cells constitute the inner lining
of the vessels and are a cornerstone of vascular homeos-
tasis. Besides its classical barrier function, the endothe-
lium is a key player in physiological processes such as
the regulation of vasomotor tone, the control of tissue
inflammation and of thrombosis [1,2]. Within the renal
microvasculature, the endothelium is characterized by a
remarkable structural heterogeneity, related to the dif-
ferent and highly specialized functions of endothelial
cells, from the preglomerular arterioles to the peritubu-
lar capillary bed.
The term “endothelial dysfunction” has been used to
define diverse syndromes characterized by changes in dis-
tinct endothelial functions, related to a cellular phenotypic
switch from a quiescent to an activated state. No clear
definition of endothelial dysfunction has been established
so far, and this multifaceted disorder actually encompasses
a spectrum of disturbances in vasomotor responses,
antithrombogenic properties, vascular permeability, leuko-
cyte recruitment and endothelial cell proliferation. In the
clinical setting endothelial dysfunction may be detected
non-invasively by functional tests evaluating the vasomo-
tor effects of pharmacological substances such as acetyl-
choline, or of flow-mediated vasodilation after transient
ischemia on distal conduit arteries [3,4]. Considerable
interest has also been focused on the identification of cir-
culating markers associated with endothelial dysfunction.
These include endothelin 1 (ET-1), metabolites of NO
(nitrites, nitrates), markers of fibrinolysis and anticoagu-
lant activity (plasminogen activator inhibitor 1, soluble
thrombomodulin), and soluble endothelial adhesion mole-
cules (s-E-selectin, s-ICAM, s-VCAM) [5]. More recently
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tive markers of endothelial cell dysfunction [6].
Cardiovascular outcomes are the major cause of death in
end-stage renal disease patients [7]. During the past dec-
ade endothelial dysfunction has emerged as an important
intermediate factor in CKD. Indeed, with the decreasing
glomerular filtration rate, the vasculature is progressively
exposed to a burden of pathogenetic conditions responsi-
ble for severe functional changes in the endothelium, such
as reactive oxygen species (ROS), assymetrical dymethylar-
ginine (ADMA), homocysteine or glycosylated end pro-
ducts [8-11]. We and others have identified ADMA, an
endogenous inhibitor of NO synthase (NOS) elevated in
CKD patients, as a mediator of endothelial dysfunction,
oxidative stress and fibrogenesis [12,13]. Oxidative stress
plays an important role in cellular responses to injury, and
is a central process in the pathophysiology of endothelial
dysfunction. In endothelial cells, ROS can be generated by
uncoupled eNOS, which normally produces NO, and lead
to the production of oxygen peroxide and subsequent
modifications of the cellular phenotype [2,14].
Although the recognition of a systemic endothelial
disease related to CKD has led to significant research
interest, fewer studies have specifically focused on
endothelial alterations within the diseased kidney. We
have shown that pharmacological NO deficiency led to
ET-1 production in the injured renal endothelial cells
with direct profibrotic consequences in the kidney [15].
Recent evidence provides novel insights on the patho-
physiological role of intrarenal endothelium in the pro-
gression of CKD (Figure 1). In this review we analyze
direct and indirect consequences of endothelial altera-
tions on hemodynamics, inflammation and fibrogenesis
in the kidney, and discuss therapeutic issues targeting
this underestimated culprit in renal fibrosis.
Review
Renal endothelial injury contributes to parenchymal
hypoxia
Chronic hypoxia mediates the progression of renal fibro-
sis, even from the early stages of CKD [16]. Interstitial
fibroblasts, epithelial cells and endothelial cells develop
different responses to hypoxia, which may directly or
indirectly contribute to profibrotic mechanisms. Human
renal fibroblasts exposed to experimental hypoxic condi-
tions increase collagen production and decrease the
expression of extracellular matrix remodeling enzymes
[17]. Aerobic oxidative metabolism-dependent epithelial
cells physiologically adapt to a reduction in oxygen ten-
sion by increasing HIF (hypoxia inducible factor)-depen-
dent signaling, which in turn promotes cell survival [18].
In chronic hypoxic conditions these tubular adaptive
mechanisms may be overrun and cell function and viabi-
lity compromised.
Although the endothelium receives direct oxygen sup-
ply from red blood cells, global or regional hemodynamic
disturbances may also be responsible for endothelial
hypoxia and activate the endothelial cells. In a rat model
o fr e n a la r t e r yc l a m p i n gw i t hr e s c u eb yn o n - i n j u r e d
endothelial cells, Brodsky and colleagues identified acute
endothelial dysfunction as a contributor to the hemody-
namic “no-reflow” phenomenon in post-ischemic kidneys
[19]. In this setting, endothelial activation and subse-
quent adhesion of leukocytes to the endothelium was
believed to create hemodynamic resistances which reduce
regional blood flow.
Peritubular capillaries constitute the major network sup-
plying oxygen to the nephrons. Therefore capillary func-
tional alterations, by reducing blood flow or leading to
subsequent reduction of vascular density, are susceptible
to be a major determinant of kidney disease progression.
Consistently, studies on human biopsies have associated
microvascular rarefaction with the progression of renal
failure, while evidence for a pathogenetic role of capillary
endothelial alterations in CKD progression via chronic
tubulointerstitial hypoxia stems from experimental mod-
els. In renal biopsies of CKD patients, Choi and colleagues
have demonstrated that morphological alterations of peri-
tubular capillaries were strongly associated with para-
meters of tubulointerstitial injury [20]. Similarly a
histomorphological evaluation of cadaveric kidney allo-
grafts performed at the time of transplantation showed
that sustained kidney injury is associated with a reduction
in Von Willebrand Factor staining on peritubular capil-
laries (but not on renal arteries or arterioles) [21]. In
experimental renovascular disease therapeutic prevention
of vascular rarefaction by intrarenal administration of
VEGF leads to the preservation of renal blood flow and a
reduction in subsequent fibrosis [22]. Together with sev-
eral other studies, these results suggest straightforward
pathophysiological consequences of peritubular endothe-
lial alterations on both short- and long-term aspects of
renal function.
Interlobular arteries and afferent arterioles are the major
site for renal blood flow autoregulation. Since endothelial
cells control vasomotor tone in these resistance vessels, in
particular via NO and endothelium-derived hyperpolariz-
ing factors, alterations of the endothelium may also contri-
bute to glomerular hemodynamic disturbances and to
downstream hypoxia in the kidney. Fawn-Hooded hyper-
tensive (FHH) rats present defective renal blood flow auto-
regulation and develop progressive kidney failure with age.
Ochodnicky and colleagues have studied endothelium-
dependent vasodilation in this inbred model of sponta-
neous renal disease and identified that endothelial
dysfunction in the renal artery precedes the development
of kidney damage [23]. Although the mechanistic explana-
tions for these results presumably differ from those related
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establishes that the integrity of preglomerular endothelium
is required for renal vascular homeostasis.
Overall, current evidence underlines renal endothelial
hypoxia as the actor of an important profibrotic vicious
circle in CKD progression (Figure 1).
Endothelial functional alterations promote tissue
inflammation
Exaggerated inflammation has long been identified as a
major player in acute and chronic renal diseases, including
allograft rejection, glomerulonephritis, ischemia-reperfu-
sion or cisplatin-induced nephropathy. The endothelium
is at the interface between blood and circulating cells on
the one hand, and tissue on the other hand. In physiologi-
cal and pathological conditions, endothelial cells integrate
mechanical stimuli related to local hemodynamics and
cytokinic stimuli such as IFN-gamma, IL-1beta or TNF-
alpha. The latter cytokines are able to induce the expres-
sion of distinct patterns of adhesion molecules on the
luminal surface, thereby promoting a site- and cell-specific
recruitment of circulating leukocytes. Schematically leuko-
cyte recruitment is a three-step process. Leukocytes first
roll on the activated endothelium, via the interaction
between selectins (E-selectin, P-selectin) and leukocyte
surface antigens. Firm adhesion is then facilitated by the
endothelial expression of ICAM-1 and VCAM-1, which
also promote subsequent transmigration of the leukocytes
into the tissue, together with PECAM/CD31.
In the kidney pathophysiological implications of
endothelial selectins and adhesion molecules have been
demonstrated in a large variety of clinical settings and
experimental models. In an ischemic model of renal failure,
P-selectin blockade with monoclonal antibodies improved
renal function and the administration of fucoidan, an oligo-
saccharide which non-specifically inhibits P-selectin,
increased renal blood flow [24]. Similarly, transgenic mice
lacking basigin/CD147, a ligand for E-selectin, exhibited
reduced kidney damage after ischemia-reperfusion as
compared to control mice, indicating a critical role for
E-selectin in neutrophil recruitment in this setting [25]. In
rodents, the injection of allo-immune nephrotoxic serum
induced the expression of endothelial selectins and leuko-
cyte rolling in glomeruli and capillaries, an event that was
significantly blunted by fucoidan in postcapillary venules
[26,27].
By using anti-ICAM-1 monoclonal antibodies in rats
and ICAM-1 transgenic mice, Kelly and colleagues have
shown that this adhesion molecule plays an early and
important pathogenetic role in renal ischemia-reperfu-
sion, via neutrophil infiltration, with both functional and
structural consequences on the kidney [28,29]. Adhesion
of circulating cells to the endothelium of renal vessels
may also contribute to potentially severe hemodynamic
alterations, which can further aggravate tissue injury.
Overall these studies underline the importance of
endothelial activation in the genesis of local inflammation
at early stages of inflammatory kidney diseases.
Figure 1 Schematic view of the pathophysiological role of endothelial activation in chronic kidney disease progression.( A D M A
assymetrical dymethylarginine; ROS reactive oxygen species; AGE advanced glycation end products; TGF transforming growth factor; TNF tumor
necrosis factor; IL interleukin; IFN interferon; EndMT endothelial-mesenchymal transition; Cx40 Connexin 40: Cx43 Connexin 43.)
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in the coordination and integration of microvascular func-
tion by the endothelial cells in a very complex manner.
Gap junctions are composed of intercellular channels
formed by connexins (Cx), which allow the direct
exchange of ions, small metabolites and other second mes-
senger molecules between adjacent cells [30]. Each type of
Cx-made channel has a unique inherent gating property,
or permeability to various molecules. Therefore, Cx com-
position of gap junction channels appears to determine
selectivity among second messengers [31].
Alterations of the expression of endothelial Cx have
been associated to the development of chronic and acute
vascular inflammatory diseases [32]. For example, a
decrease in the expression of Cx40 has been reported in
the endothelial layer covering atherosclerotic lesions in the
aorta of hypercholesterolemic mice. Mice in which Cx40
was specifically deleted from the endothelium showed
enhanced monocyte infiltration at the very early stages of
the disease [33]. In contrast to Cx40, Cx43 expression
seems to be upregulated in the dysfunctional endothelium
and endothelium-specific deletion of Cx43 in mice greatly
reduced the TNF-a-induced leukocyte adhesion and
transmigration [34]. It has also been recently suggested
that this Cx may serve as a conducting pathway by ampli-
fying Ca
2+-signalling between endothelial cells to spread
inflammatory signals within the lung capillary network
[35]. In addition, Cx43
+/- mice were protected against
chronic or acute inflammatory disease, as they displayed
reduced inflammatory cell recruitment at the injured site
[32]. Interestingly, in accordance with the above men-
tioned studies, we recently observed a marked increase of
the expression of Cx43 in the endothelium of peritubular
and glomerular capillaries at the early stages of hyperten-
sion-induced renal disease in mice. The Cx43 expression
pattern was paralleled closely by that of adhesion markers
such as VCAM-1 and ICAM-1, known to play a major
role in the recruitment of inflammatory cells [36].
Although further work is required to clarify the implica-
tion of Cx in renal inflammation, the Cx hypothesis may
be of interest in the recruitment of inflammatory cells in
the kidney, as several studies showed an important role of
these proteins in the inflammatory response.
Endothelial-mesenchymal transition: a new player in renal
fibrosis?
The origin of renal fibroblasts is an evolving and some-
what controversial issue [37-39]. Acquisition of a
mesenchymal-like phenotype by tubular epithelial cells,
named epithelial-mesenchymal transition (EMT), has
been largely studied in renal fibrosis over the past decade.
More recently several research teams have suggested that
endothelial cells may also acquire functional and struc-
tural characteristics of mesenchymal cells after tissue
injury. This so-called endothelial-mesenchymal transition
(EndMT) had previously been recognized in normal con-
ditions, particularly during embryonic development of
the heart. Increasing evidence now argues that EndMT
m a yp l a ya na d d i t i o n a lr o l ei nav a r i e t yo fd i s e a s e s ,
including in kidney injury [40].
In vitro, endothelial cells of different origins can acquire
a mesenchymal phenotype, spontaneously or after stimula-
tion by TGF beta. In a model of cardiac overload in Tie2-
Cre;ROSA-STOP-lacZ transgenic mice, the presence of
markers usually expressed by myofibroblasts (FSP-1, alpha
SMA) was partially co-localized with the endothelial fate
tracer lacZ, suggesting the endothelial origin of heart myo-
fibroblasts [41]. Interestingly mice treated with human
recombinant BMP-7 appeared to be protected against
both EndMT and the development of cardiac fibrosis.
During the past 4 years, an EndMT-like process has also
been evidenced in the kidney in several independent
experimental models (unilateral ureteral obstruction, phar-
macological inhibition of eNOS, streptozotocin-induced
nephropathy, Col4a3-deficient mice) [42-44]. We have
also evaluated the modifications of endothelial-cell pheno-
type during the progression of angiotensin II-induced
nephropathy in Sprague Dawley rats, and observed a lim-
ited and focal co-expression of FSP1 with the endothelial
marker RECA1, which suggests the presence of EndMT in
peritubular renal capillaries in hypertensive nephropathy.
Interestingly, features consistent with EndMT were
observed at early stages of the renal disease, before the
onset of significant proteinuria or fibrosis (Guerrot et al.,
unpublished data). Recently, Basile and collegues have
analyzed the phenotypic alterations of endothelial cells
after ischemia-reperfusion in Tie2-Cre;YFP transgenic
mice [45]. The results of this study suggested that the
reduced density of endothelial cells following renal ische-
mia may be due, in part, to EndMT.
Together, these data identify EndMT as a novel aspect
of endothelial dysfunction and show that EndMT may be
associated with kidney disease. Furthermore, they suggest
that endothelial cells which acquire mesenchymal charac-
teristics may directly contribute to early pathogenetic
mechanisms of fibrogenesis. However, owing to the het-
erogeneity of renal endothelial cells, further studies would
be of major interest to better understand the relative
importance, the molecular mechanisms and local conse-
quences of EndMT, especially with respect to the different
compartments of renal microvasculature.
Targeting renal endothelial dysfunction as an innovative
therapeutical approach in renal fibrosis
Since current evidence underlines the importance of
endothelial alterations in CKD progression, the prevention
of renal endothelial injury emerges as a promising treat-
ment strategy in kidney diseases. Depending on the clinical
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ble to alleviate inflammation, hemodynamic disturbances,
hypoxia and extracellular matrix synthesis. In renal experi-
mental models, interesting studies have suggested benefi-
cial effects of therapies based on selectin inhibitors, ET-1
antagonists or treatments increasing NO bioavailability
[15,46-48]. These strategies all target distinct aspects of
endothelial pathophysiology, thereby reducing specific
consequences of renal endothelial functional alterations.
In a different approach several teams have also shown pro-
mising results when promoting replacement of the injured
endothelium, either by increasing resident endothelial cell
proliferation, stimulating endogenous progenitor mobiliza-
tion or directly injecting autologous endothelial progenitor
cells into the kidney [49-51].
An important characteristic of endothelial activation in
kidney diseases is de novo expression of surface antigens.
Importantly, critical modifications of the endothelial phe-
notype predominantly occur in the injured region. There-
fore, specifically targeting the activated endothelial cells
may allow selective delivering of drugs to the diseased vas-
cular bed. This strategy has proven to be efficient in preli-
minary studies using liposomes conjugated to anti-E-
selectin antibodies, to address dexamethasone in a model
of allo-immune nephrotoxic serum-induced renal disease
[27,48].
Conclusion
Endothelial dysfunction is a multifaceted disorder that
plays a central role in complications related to kidney dis-
eases. Beside the well established systemic endothelial dys-
function associated with CKD, recent evidence highlights
direct implications of renal endothelial activation in fibro-
genesis. Together these data suggest that the altered renal
endothelium may be a promising therapeutic target and
prompt further studies to evaluate novel specific strategies
for the treatment of CKD progression. Specifically, the
possibility of targeted delivery based on endothelial altera-
tions opens novel therapeutic avenues for the treatment of
renal diseases. Future research directions may also include
inhibition of EndMT, preservation of endothelium-derived
hyperpolarizing factors, pharmacological maintenance of
eNOS activation in altered shear stress conditions, and
silencing of endothelial proinflammatory genes.
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